Tuberculosis-associated hemophagocytic lymphohistiocytosis: diagnostic challenges and determinants of outcome

Lisa Kurver,Timothy Seers,Suzanne van Dorp,Reinout van Crevel,Gabriele Pollara,Arjan van Laarhoven

DOI: https://doi.org/10.1093/ofid/ofad697

2024-01-11

Open Forum Infectious Diseases

Abstract:Abstract Background Tuberculosis (TB) can induce secondary hemophagocytic lymphohistiocytosis (HLH), a severe inflammatory syndrome with high mortality. We integrated all published reports of adult HIV-negative TB-associated HLH (TB-HLH) to define clinical characteristics, diagnostic strategies and therapeutic approaches associated with improved survival. Methods PubMed, Embase, and Global Index Medicus were searched for eligible records. TB-HLH cases were categorized into patients with a confirmed TB diagnosis receiving antituberculosis treatment while developing HLH, and patients presenting with HLH of unknown cause later diagnosed with TB. We used a logistic regression model to define clinical and diagnostic parameters associated with survival. Results We identified 115 individual cases, 45 (39.1%) from low TB incidence countries (<10/100.000 per year). Compared to HLH patients with known TB (n = 21), patients with HLH of unknown cause (n = 94), more often had extrapulmonary TB (66.7% vs. 88.3%), while the opposite was true for pulmonary disease (91.5% vs. 59.6%). Overall, Mycobacterium tuberculosis was identified in the bone marrow in 78.4% of patients for whom examination was reported (n = 74). Only 10.5% (4/38) of patients tested had a positive tuberculin skin test or interferon gamma release assay. In-hospital mortality was 28.1% (27/96) in those treated for TB and 100% (18/18) in those who did not receive antituberculosis treatment (p < 0.001). Conclusions Tuberculosis should be considered as a cause of unexplained HLH. TB-HLH is likely to be under-reported, and the diagnostic work-up of HLH patients should include bone marrow investigations for evidence of M. tuberculosis. Prompt initiation of antituberculosis treatment likely improves survival in TB-HLH.

immunology,infectious diseases,microbiology

What problem does this paper attempt to address?

This paper aims to address the diagnostic challenges of Tuberculosis - associated Hemophagocytic Lymphohistiocytosis (TB - HLH) and the factors influencing survival rates. Specifically, by integrating all published case reports of TB - HLH in non - HIV - infected adults, the researchers defined the clinical features of this disease, diagnostic strategies, and treatment regimens associated with improved survival rates.

### Research Background
Tuberculosis (TB) can induce secondary Hemophagocytic Lymphohistiocytosis (HLH), which is a severe inflammatory syndrome with a high mortality rate. HLH is characterized by excessive inflammatory responses, including high - level production of pro - inflammatory cytokines, excessive activation of macrophages, and phagocytosis of mature blood cells.

### Research Objectives
1. **Define Clinical Features**: Clarify the clinical manifestations of TB - HLH patients.
2. **Diagnostic Strategies**: Explore effective diagnostic methods, especially the importance of bone marrow examination in diagnosis.
3. **Treatment Regimens**: Evaluate the impact of different treatment methods on patient survival rates, especially the positive impact of timely initiation of anti - tuberculosis treatment on survival rates.

### Main Findings
- **Clinical Features**: Most TB - HLH patients present with extrapulmonary tuberculosis, especially bone marrow involvement, while the proportion of pulmonary tuberculosis is relatively low.
- **Diagnostic Challenges**: Traditional T - cell detection methods (such as tuberculin skin test (TST) and interferon - gamma release assay (IGRA)) often show negative or non - reactive results in HLH patients, which increases the difficulty of diagnosis.
- **Treatment Efficacy**: The mortality rate during hospitalization of patients receiving anti - tuberculosis treatment was 28.1%, while the mortality rate of patients not receiving anti - tuberculosis treatment was as high as 100%. This indicates that timely initiation of anti - tuberculosis treatment is a key factor in improving survival rates.

### Conclusions
- **Diagnostic Recommendations**: In HLH patients without a clear cause, the possibility of tuberculosis should be considered, and bone marrow examination should be performed to look for evidence of Mycobacterium tuberculosis.
- **Treatment Recommendations**: Timely initiation of anti - tuberculosis treatment can significantly improve the survival rate of TB - HLH patients.

### Key Points
- Hemophagocytic Lymphohistiocytosis is an under - reported complication of tuberculosis, often presenting as extrapulmonary or miliary lesions.
- TST and IGRA usually show non - reactivity.
- For suspected or diagnosed HLH patients, the threshold for bone marrow examination should be lowered, and anti - tuberculosis treatment should be started in a timely manner.

This paper, through systematic review and meta - analysis, provides important guidance for clinicians, emphasizes the importance of considering tuberculosis in HLH patients, and proposes specific diagnostic and treatment recommendations.